Quanterix Reports 34% Revenue Growth to $32.9 Million in Q2 2026 Despite Net Loss

Quanterix Corporation reported a significant increase in its financial performance for the second quarter of 2026, with total revenues reaching $32.9 million, a 34% increase from $24.5 million in the same period last year. For the first half of 2026, revenues totaled $69.3 million, up 26% from $54.8 million in the first half of 2025. The growth was primarily driven by a 39% increase in product revenue, which amounted to $23.5 million, largely attributed to the acquisition of Akoya Biosciences, which contributed $9.3 million in product sales. However, the legacy Quanterix business experienced a decline in product revenue due to reduced demand from academic and pharmaceutical customers.

Despite the revenue growth, Quanterix reported a net loss of $48.9 million for the second quarter, compared to a loss of $30.0 million in the same quarter of 2025. The company’s operating expenses rose significantly, totaling $62.1 million, a 32% increase from $47.1 million in the prior year, largely due to a $26.9 million impairment charge related to goodwill from the Akoya acquisition. The increase in operating expenses was also influenced by higher costs associated with the integration of Akoya and ongoing restructuring efforts.

Operationally, Quanterix has made strides in expanding its customer base, with over 2,500 instruments installed globally and more than 6,800 scientific publications citing its technology. The company has also focused on enhancing its product offerings, particularly in Alzheimer’s diagnostics, with the recent submission of a 510(k) premarket notification to the FDA for a multi-analyte blood test. The company aims to leverage its proprietary Simoa technology to drive diagnostic innovation and improve early-stage disease detection.

In terms of financial health, Quanterix reported cash and cash equivalents of $44.2 million and marketable securities of $49.4 million as of June 30, 2026. The company experienced a net cash outflow of $23.2 million from operating activities during the first half of 2026, an increase from $19.5 million in the same period of 2025. The company anticipates continued operating losses as it invests in research and development, commercial initiatives, and infrastructure improvements, with a revised expectation to reach cash flow breakeven in 2027.

Looking ahead, Quanterix is focused on executing its strategic initiatives to enhance revenue growth, particularly in the Alzheimer’s diagnostics market. The company plans to streamline its product roadmap and invest in marketing and sales efforts to strengthen its competitive position. While the uncertain macroeconomic environment poses challenges, Quanterix remains optimistic about its ability to recover instrument demand and expand its market presence in the coming years.